Adam S. Kibel, MD

Adam S. Kibel, MD

Brigham and Women's Hospital

Boston, Massachusetts

Adam S. Kibel, MD, is currently serving as the Chief of Urology at Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center. In addition, he is a Professor of Surgery at Harvard Medical School. Dr. Kibel graduated from Cornell University School of Medicine, completed his residency at Brigham and Women’s Hospital, and a fellowship at Johns Hopkins. Dr. Kibel has authored more than 250 peer-reviewed publications. In both his practice and research, he focuses on minimally invasive techniques to treat urologic cancers, including improved imaging and identification of molecular markers of urologic tumors. Dr. Kibel received two awards in 2019: the Boston Magazine Top Doctor and Castle Connolly America's Top Doctors.

Articles by Adam S. Kibel, MD

Management of Localized High-Risk Prostate Cancer

Adam S. Kibel, MD, argues that aggressive curative therapy is the best practice for the management of high-risk prostate cancer. He observes that local therapies like surgery, along with combination therapies like external beam radiation therapy plus brachytherapy and androgen deprivation therapy, have shown themselves to be effective for improving overall survival.

Read More

Surgery versus Radiation Therapy – A Surgeon’s Perspective

Adam S. Kibel, MD, argues that the preponderance of evidence shows surgery outperforming radiation therapy when treating prostate cancer patients. He discusses the randomized data still needed to accurately compare these two treatments and multiple case series and a meta-analysis that favor surgery in terms of overall survival, as well as the benefit of surgery in terms of providing an opportunity for optimal staging and subsequent treatment.

Read More

Neoadjuvant Therapy for High-Risk Prostate Cancer

Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.

Read More

Join the GRU Community

- Why Join? -